C10 Labs Research
Investment Thesis
C10 Labs is an MIT-born AI venture studio and fund based in Cambridge, Massachusetts (Kendall Square) with a second hub in New York City. It was founded in 2023 by Shahid Azim, Dr. Patricia Geli, and MIT Media Lab Professor Ramesh Raskar, who met co-teaching MIT's "AI for Impact" venture studio class. The firm's thesis is that AI is moving "beyond screens" into what it calls "Dimensional AI" — AI systems that act on and transform physical-world industries rather than just software interfaces. C10 Labs pairs studio-style company building (cohort programs, operator support, technical resources) with direct capital, positioning itself as a co-builder rather than a passive check-writer.
Sector Focus
C10 Labs states an initial focus on healthcare, agriculture, transportation, and energy as the industries AI will most transform, while its realized portfolio skews toward applied AI in healthcare/clinical research, biotech, enterprise data infrastructure, and future-of-work tooling. Confirmed portfolio companies span digital health/dermatology AI (MyMonitor.ai), biotech drug discovery (Alpha Cure Therapeutics), enterprise AI/semantic data infrastructure (ekai), and AI-driven HR/hiring tools (ReechOut). The firm also runs a dedicated "AI BioHub" accelerator track with LabCentral focused specifically on AI-in-biotech founders.
Stage Focus
C10 Labs invests at the earliest stages — pre-seed and seed — consistent with its cohort/accelerator model. Its cohorts (Winter Cohort, NYC AI Nexus, AI BioHub) admit early-stage teams, often pre-product or pre-revenue, and provide capital alongside a structured multi-month program (roughly four months per cohort).
Check Size
Exact check size is not publicly disclosed. Observed behavior (e.g., its participation in ekai's $1.7M pre-seed round led by Misneach) shows C10 Labs writing smaller participating checks alongside a lead investor rather than leading rounds itself, consistent with a studio/accelerator capital structure layered on top of its cohort investment.
Lead Tendency
Based on available evidence, C10 Labs typically follows or co-invests alongside a lead (e.g., participating in Misneach-led rounds) rather than leading. No confirmed instance of C10 Labs leading a priced round was found in public sources.
Recent Activity
C10 Labs remains actively deploying. In July 2024, SEC filings reported the firm had raised approximately $77.9M from 18 investors for its studio/fund vehicle. Most recently, in September 2026, C10 Labs participated in ekai's $1.7M pre-seed round (enterprise AI semantic-context infrastructure), led by Misneach. The firm continues to run recurring cohort programs: a Fall 2026 NYC AI Nexus cohort, and an AI BioHub accelerator co-run with LabCentral that has run at least two cohorts (most recently beginning March 2026).
Portfolio Highlights
C10 Labs' public portfolio page states 40+ AI-first companies across HealthTech, Biotech, LegalTech, and other verticals. Confirmed named portfolio companies include: MyMonitor.ai (AI-powered, melanin-aware dermatology assessment platform for clinical trials and dermatology clinics), Alpha Cure Therapeutics (precision, non-radioactive radioligand cancer therapy), ReechOut (AI voice check-in / hiring platform), and ekai (semantic data-context layer for enterprise AI agents, backed alongside Misneach). Public materials also cite that across its early cohorts, 38 founders had collectively raised $18M+ in follow-on capital.
Team
- Shahid Azim — Co-Founder, CEO & Managing Partner. Prior operator background including Quanttus, a VC-backed continuous blood-pressure-monitoring wearable startup that predated the Apple Watch.
- Dr. Patricia Geli — Co-Founder, Managing Partner & COO.
- Prof. Ramesh Raskar — Co-Founder & Chief Scientist; MIT Media Lab professor; co-taught the "AI for Impact" course that led to C10 Labs' founding.
- Javad Mushtaq — Managing Director, NYC & Head of the NYC AI Nexus program, leading C10 Labs' New York expansion; background from Harvard and MIT.
Decision Process
C10 Labs operates as a partnership among its three co-founders (Azim, Geli, Raskar), with regional leadership (e.g., Mushtaq in NYC) running localized programs. The studio/fund structure suggests a partnership-style decision process rather than a solo-GP or formal investment-committee model.
Founder Preferences
C10 Labs favors technical, often research-adjacent founders building applied AI products in regulated or operationally complex industries (healthcare, biotech, enterprise data). Several founders in its cohorts come from academic or research backgrounds (e.g., Harvard/MIT), consistent with the firm's MIT Media Lab origins and its emphasis on deep technical expertise over generalist consumer-startup profiles.
Geographic Focus
Primarily Boston/Cambridge (Kendall Square, via a CIC partnership hub) and New York City (NYC AI Nexus). The firm also participates in the Massachusetts AI Hub initiative and partners with organizations like RIHub to extend its pipeline into New England more broadly.